JBF Capital’s Crescent Biopharma CBIO Stock Holding History

JBF Capital’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150	Closed	-$56K	–	93
2020 Q4	$56K	Hold	150	–	–	0.01%	50
2020 Q3	$46K	Buy	+150	New	+$57.3K	0.01%	110

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JBF Capital's CBIO Position: Q1 2021 in Review

JBF Capital sold out of Crescent Biopharma (CBIO) in Q1 2021, closing a stake of 150 shares — an estimated $56K sold.

JBF Capital first reported a position in CBIO in Q3 2020 and held it in 2 quarters. The position peaked at $56K in Q4 2020. 78 funds tracked by Wall St. Rank hold CBIO as of Q1 2021.

JBF Capital reported no remaining Crescent Biopharma position as of Q1 2021 after selling out during the quarter.
JBF Capital sold 150 Crescent Biopharma shares in Q1 2021, an estimated $56K.
JBF Capital first reported a position in Crescent Biopharma in Q3 2020 and held it in 2 quarters.
JBF Capital's Crescent Biopharma position peaked at $56K in Q4 2020.
78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2021.

Based on JBF Capital's 13F filing for Q1 2021, filed 13 May 2021.